FindTrial
Sign In

The role of HMGB1-CAV-1 signal transduction on endothelial cell barrier dysfunction in preeclampsia

The role of HMGB1-CAV-1 signal transduction on endothelial cell barrier dysfunction in preeclampsia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014385
Enrollment
Unknown
Registered
2018-01-10
Start date
2018-01-09
Completion date
Unknown
Last updated
2018-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia

Interventions

Two groups:none

Sponsors

Shanghai Jiaotong University No.6 People's hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Maternal maximum systolic blood pressure 160 mmHg and/or diastolic blood pressure 110 mmHg on admission was defined as severe preeclampsia. Twenty women with severe PE at 25-32 weeks of gestation and twenty women with uncomplicated pregnancies at the same period were enrolled in this study.

Exclusion criteria

Exclusion criteria: None of the patients had a medical history of liver or kidney disease, diabetes, primary hypertension, or other cardiovascular diseases.

Design outcomes

Primary

MeasureTime frame
HMGB1;—

Countries

China

Contacts

Public ContactRongzhen Jiang

Shanghai Jiaotong University 6th People's hospital

jianrzh@163.com+86 18930172722

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026